title: Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion.
abstract: Mouse skin carcinomas arise from a small subpopulation of benign papillomas with an increased risk of malignant conversion. These papillomas arise with limited stimulation by tumor promoters, appear rapidly, and do not regress, suggesting that they differ in growth properties from the majority of benign tumors. The transforming growth factor beta (TGF-beta) proteins are expressed in the epidermis and are growth inhibitors for mouse keratinocytes in vitro; altered TGF-beta expression could influence the growth properties of high-risk papillomas. Normal epidermis, tumor promoter-treated epidermis, and skin papillomas at low risk for malignant conversion express TGF-beta 1 in the basal cell compartment and TGF-beta 2 in the suprabasal strata. In low-risk tumors, 90% of the proliferating cells are confined to the basal compartment. In contrast, the majority of high-risk papillomas are devoid of both TGF-beta 1 and TGF-beta 2 as soon as they arise; these tumors have up to 40% of the proliferating cells in the suprabasal layers. Squamous cell carcinomas are also devoid of TGF-beta, suggesting that they arise from the TGF-beta-deficient high-risk papillomas. In some high-risk papillomas, TGF-beta 1 loss can occur first and correlates with basal cell hyperproliferation, while TGF-beta 2 loss correlates with suprabasal hyperproliferation. Similarly, TGF-beta 1-null transgenic mice, which express wild-type levels of TGF-beta 2 in epidermis but no TGF-beta 1 in the basal layer, have a hyperproliferative basal cell layer without suprabasal proliferation. In tumors, loss of TGF-beta is controlled at the posttranscriptional level and is associated with expression of keratin 13, a documented marker of malignant progression. These results show that TGF-beta expression and function are compartmentalized in epidermis and epidermal tumors and that loss of TGF-beta is an early, biologically relevant risk factor for malignant progression.
authors.affiliation: Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: A B
authors.initials: AB
authors.lastname: Glick
authors.forename: A B
authors.initials: AB
authors.lastname: Kulkarni
authors.forename: T
authors.initials: T
authors.lastname: Tennenbaum
authors.forename: H
authors.initials: H
authors.lastname: Hennings
authors.forename: K C
authors.initials: KC
authors.lastname: Flanders
authors.forename: M
authors.initials: M
authors.lastname: O'Reilly
authors.forename: M B
authors.initials: MB
authors.lastname: Sporn
authors.forename: S
authors.initials: S
authors.lastname: Karlsson
authors.forename: S H
authors.initials: SH
authors.lastname: Yuspa
mesh_terms: D000818:Animals; D001483:Base Sequence; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000209:etiology / Q000473:pathology; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D000078404:Epidermal Cells; D004817:Epidermis / Q000737:chemistry*; D005260:Female; D007633:Keratins / Q000032:analysis; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D010212:Papilloma / Q000737:chemistry / Q000209:etiology / Q000473:pathology; D012306:Risk; D012878:Skin Neoplasms / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000032:analysis*
chemical_list: D016212:Transforming Growth Factor beta; D007633:Keratins